

Appendix VI: 2004 Publications

SMBD – Jewish General Hospital

Baron, Murray

--Sewitch MJ, Dobkin PL, Bernatsky S, **Baron M**, Starr M, Cohen M, Fitzcharles MA. Medication non-adherence in women with fibromyalgia. *Rheumatology (Oxford)*, 43:648-54, 2004

--Pukall C, **Baron M**, Amsel R, Khalifé F, Binik Y. Tender point examination in women with vulvar vestibulitis syndrome. Submitted 2004.

--Pope J, Lee P, **Baron M**, Dunne J, Smith D, Docherty P, Bookman A, Abu-Hakima M. The prevalence of pulmonary arterial hypertension in a large Canadian multi-center cohort of systemic sclerosis subjects. Submitted 2004.

--Penrod JR, Bernatsky S, Adam V, **Baron M**, Dayan N, Dobkin PL. Health services costs and their determinants in women with fibromyalgia. *J Rheumatol.*, 31:1391-8, 2004

--Kang H, **Baron M**, Glikstein R. Shoulder Hemarthrosis Due to a Bleeding Pseudo-aneurysm. *Journal of Clinical Rheumatology*, Published online: 10 December 2004.

--Kang H, **Baron M**. Embolic Complications of a Mitral Valve Rheumatoid Nodule. *J Rheumatol*: 1001-3, 2004

--Bykerk V, **Baron M**, Boire G, Haraoui B, Khraishi M, LeClercq S, Pope J, Keystone E. Canadian Consensus Statement on Early Optimal Therapy in Early Rheumatoid Arthritis. *J Can Rheumatol Assoc.*, 14:11-13, 2004

---**Baron M**, Bell M, Bookman A, Jerome D, Kaminska E, Lupton T, Pope J, the Canadian Scleroderma Research Group. Reliability and Validity of Ophthalmoscopic Capillaroscopy. submitted 2004

Beitel, Lenore

--Elhaji YA, Wu JH, Gottlieb B, **Beitel LK**, Alvarado C, Batist G and Trifiro MA. An examination of how different mutations at arginine 855 of the androgen receptor result in different androgen insensitivity phenotypes. *Mol Endocrinol* 18: 1876-1886, 2004

--Gottlieb B, **Beitel LK**, Wu J, Elhaji YA and Trifiro M. Nuclear receptors and disease: androgen receptor. *Essays Biochem* 40:121-36: 121-136, 2004

--Gottlieb B, **Beitel LK**, Wu JH and Trifiro M. The androgen receptor gene mutations database (ARDB): 2004 update. *Hum Mutat* 23: 527-533, 2004

--Zhang Y, Champagne N, **Beitel LK**, Goodyer CG, Trifiro M and LeBlanc A. Estrogen and androgen protection of human neurons against intracellular amyloid beta1-42 toxicity through heat shock protein 70. *J Neurosci* 24: 5315-5321, 2004

Béland, François

--Zunzunegui MV., Koné M., Jorhi M., **Béland F**, Wolfson C., Bergman H. Social Networks and self-rated health in two French-speaking Canadian community dwelling population over 65, *Social Science & Medicine*, 58:2069-2081, 2004

--Dedobbeleer N, **Béland F**, Contandriopoulos AP, Adrian M. Gender and the social context of smoking behaviour, *Social Science & Medicine*, 58:1-12, 2004

Bergman, Howard

--**Bergman H.**, Béland F., Karunanathan S., Humel S., Hogan D., Wolfson C. Développement d'un cadre de travail pour comprendre et étudier la fragilité, *Gérontologie et société*, 109:15-29, 2004

Blostein, Mark

--Hasanbasic, I., Cuerquis, J., Varnum, B., **Blostein, M.D.**. Intracellular signalling pathways involved in gas6-Axl mediated survival of endothelial cells. *American Journal of Physiology* 287: H1207-H1213, 2004.

--Kahn ,S.K., Elyssa E., Bornais, C., **Blostein, M.D.**, Wells, P.S. Post-thrombotic syndrome, functional disability and quality of life after upper extremity deep venous thrombosis in adults. *Thromb & Hemostasis* (in press)- *(may only be able to include this in 2005)*

Chertkow, Howard

--Phillips, N.A., **Chertkow, H.**, LeBlanc, M. Pim, H., & Murtha, S. Functional and anatomical memory indices in patients with or at risk for Alzheimer's disease. *Journal of the International Neuropsychological Society*, 10, 200-210, 2004

--Levinoff, E.J., Li, K.Z.H., Murtha, S., & **Chertkow, H.** Selective attention impairments in Alzheimer disease: Evidence for dissociable components. *Neuropsychology*.18:580-588, 2004

--Whatmough, C., Verret. L. D., Fung, D. & **Chertkow, H.** Common and contrasting areas of activation for abstract and concrete concepts: An H215O PET study. *Journal of Cognitive Neuroscience*. 16:1211-1226, 2004

--Dwolatzky, T., Whitehead, V., Doniger, G.M., Simon, E.S., Schweiger, A., Jaffe, D., & **Chertkow, H.** Validity of the Mindstreams computerized cognitive battery for Mild Cognitive Impairment. *Journal of Molecular Neuroscience*, 24:39-50, 2004

Chong, George

--Berlin, D., **Chong, G.**, Chertkow, H., Bergman, H., Phillips, N.A., & Schipper, H.M. Evaluation of HFE (hemochromatosis) mutations as genetic modifiers in sporadic AD and MCI. *Neurobiology of Aging*, 25:465-474, 2004

Clarfield, Avram

--Dwolatzky T, **Clarfield AM.** Assessment of dementia in the primary care setting. *Expert Rev. Neurotherapeutics*, 4:89-97, 2004

--**Clarfield AM**, Rosenberg E, Brodsky J, Bentur N. Healthy aging around the world: Israel too? *Israel Med Assoc J*, 6:516-520., 2004

--Wilkinson D., Lozano J.M., Ahmed T., Strauss S., **Clarfield AM**, Sliwa-Hanhle K., Marusic A., Howe A., Ioannidis J. P-A., Ward R., Mohammed I., Jesudason E., Torres T.T, Purcell G., Dandona L., Awasthi S., Li Y., Underwood T.M., Wilkes M., and Sivananthan S. ICRAM (the International Campaign to Revitalise Academic Medicine) agenda setting. *BMJ*, 329:787-9, 2004

--Ioannidis Jé P-A., Ahmed T., Awasthi S., **Clarfield AM.**, Dandona L., Howe A.C., Jesudason E.C., Li Y., Lozano JM., Marusic A., Mohammed I., Purcell G.P., Sliwa-Hahnle K., Straus SE., Edejer TT., Underwood T.J., Ward R., Wilkes M.S., Wilkinson D., and Sivanathan S. Academic medicine: the evidence base. *BMJ*, 329:789-792, 2004

--**Clarfield AM** of Longo LD, Teigen PM (eds). "Dearest G...Yours WO", William Osler' s Letters from Egypt to Grace Revere Osler .*Can Med Assoc J*, 170:833, 2004

--**Clarfield AM.** of Bonner TN. Iconoclast:Abraham Flexner and a Life in Learning. *Annals of Long Term Care*, 12:31-2, 2004

--**Clarfield AM.** Typical or atypical? It depends on your point of view. *Annals of Long Term Care*, 12:22-24, 2004

--**Clarfield AM.** Camp Doctor [II] *Annals of Long Term Care*, 12:46-7, 2004

--**Clarfield AM.** "Sorry, I told you so"[donepezil and AD 2000] *Annals of Long-Term Care*, 12:44-5, 2004

Cohen, Albert

--Yesovitch, R., **Cohen, A.** Szilagyi, A. Failure to improve parameters of lactose maldigestion using the multiprobiotic product VSL3 in lactose maldigesters: A pilot study. *Can. J. Gastroenterol.*, 18:83-86, 2004

Dascal, Andre

--**Dascal A**, Nessim S. Toxic shock syndrome in Conn's Current Therapy 2004, by Rakel RE,

and Bope T. 2004.

Duque, Gustavo

--**Duque G**, Macoritto M, Kremer R. Vitamin D treatment of senescence accelerated mice (SAM-P/6) induces several regulators of stromal cell plasticity. *Biogerontology*, 5:421-9, 2004

--**Duque G**, El Abdaimi K, Henderson JE, Lomri A, Kremer R. Vitamin D inhibits Fas ligand-induced apoptosis in human osteoblasts by regulating components of both the mitochondrial and Fas-related pathways. *Bone*, 35:57-64, 2004

--**Duque G**, Macoritto M, Kremer R. 1,25(OH)2D3 inhibits bone marrow adipogenesis in senescence accelerated mice (SAM-P/6) by decreasing the expression of peroxisome proliferator-activated receptor gamma 2 (PPARgamma2). *Exp Gerontol*, 39:333-8, 2004

Eisenberg, Mark

--**Eisenberg MJ**, Brox A, Bestawros A. Calcium-channel blockers: An update. *Am J Med.*, 116: 35-43, 2004

--**Eisenberg MJ** et al. Evaluation of routine functional testing after percutaneous coronary intervention. *Am J Cardiol*, 93:744-47, 2004

--Chee J, **Eisenberg MJ**. Impact of age on hospital course and cost of coronary artery bypass graft surgery. *Am J Cardiol*. 93:768-771, 2004

--Goldman L, Okrainec K, **Eisenberg MJ**, Schechter D et al. Six month outcomes after single and multi-lesion percutaneous coronary intervention: Results from the ROSETTA Registry. *Can J Cardiolol*. 20:608-12, 2004

--**Eisenberg MJ**, Schechter D, Lefkovits J, Goudreau E, Deligonul U, Mak KH, Duerr R, Del Core M, Garzon P, Huynh T, Smilovitch M, Sedlis S, Brown DL, Brieger D, and Pilote L. Utility of routine functional testing after PTCA: results from the ROSETTA registry. *J Inv Cardiol*. 16:318-22, 2004

--Mak KH, **Eisenberg MJ**, Tsang J, Okrainec K, Huynh T, Brown D. Clinical impact of functional testing strategy among stented and non-stented patients: insights from the ROSETTA registry. *Int J Cardiol*. 95:321-27, 2004

--Okarainec K, Benerkjee DK, **Eisenberg MJ**. Coronary artery disease in developing countries: prevalence, prevention, and control. *Am Heart J.*, 148:7-15, 2004

--Jamal S, **Eisenberg MJ**, Christopoulos S. Rhabdomyolysis associated with statin use. *Am Heart J*. 147:956 - 65, 2004

--Pilote L, Abrahamowicz M, Rodrigues E, **Eisenberg MJ**, Rahme E. Mortality rates in elderly patients who take angiotensin-converting enzyme inhibitors after acute myocardial infarction: A

class effect? *Ann Intern Med.* 141:101-112, 2004

--Babapulle MN, Joseph L, Belisle P, Brophy JM, **Eisenberg MJ**. Hierarchical bayesian meta-analysis of randomized clinical trial of drug-eluting stents. *Lancet*, 364:583-589, 2004

--**Eisenberg MJ**. Drug-eluting stents: some bare facts. *Lancet*, 364:1466-7, 2003

--Antonious, Martineau PA, Fillion KB, Haider S, Zukor DJ, Huk OL, Pilote L. **Eisenberg MJ**. In-hospital cost of total hip arthroplasty in Canada and the United States. *J Bone Joint Surg.*,86:2435-9 , 2004

Foulkes, William D.

--Al Moustafa AE, **Foulkes WD**, Benlimame N, Wong A, Yen L, Bergeron J, Batist G, Alpert L, Alaoui-Jamali MA. E6/E7 proteins of HPV type 16 and ErbB-2 cooperate to induce neoplastic transformation of primary normal oral epithelial cells, *Oncogene*, 23:350-8, 2004

--Al Moustafa AE, **Foulkes WD**, Wong A, Jallal H, Batist G, Yu Q, Herlyn M, Sicinski P, Alaoui-Jamali MA. Cyclin D1 is essential for neoplastic transformation induced by both E6/E7 and E6/E7/ErbB-2 cooperation in normal cells. *Oncogene*. 23:30:5252-6, 2004

--Bouchard L, Blancquaert I, Eisinger F, **Foulkes WD**, Evans G, Sobol H, Julian-Reynier C. Prevention and genetic testing for breast cancer: variations in medical decisions. *Soc Sci Med.*, 58:1085-96, 2004

--Brooks-Wilson AR, Kaurah P, Suriano G, Leach S, Senz J, Grehan N, Butterfield YS, Jeyes J, Schinas J, Bacani J, Kelsey M, Ferreira P, MacGillivray B, MacLeod P, Micek M, Ford J, **Foulkes W**, Australie K, Greenberg C, LaPointe M, Gilpin C, Nikkel S, Gilchrist D, Hughes R, Jackson CE, Monaghan KG, Oliveira MJ, Seruca R, Gallinger S, Caldas C, Huntsman D. Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria. *J Med Genet.*, 41:508-517, 2004

--**Foulkes WD**, Brunet JS, Stefansson IM, Straume O, Chappuis PO, Begin LR, Hamel N, Goffin JR, Wong N, Trudel M, Kapusta L, Porter P, Akslen LA. The Prognostic Implication of the Basal-Like (Cyclin high/p27low/p53+/Glomeruloid-Microvascular-Proliferation+) Phenotype of BRCA1-Related Breast Cancer. *Cancer Res.*, 64:830-835, 2004

--**Foulkes WD**, Metcalfe K, Sun P, Hanna WM, Lynch HT, Ghadirian P, Tung N, Olopade OI, Weber BL, McLennan J, Olivotto IA, Begin LR, Narod SA. Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. *Clin Cancer Res.* 10:2029-34, 2004

--**Foulkes WD**. Re: Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer. *J Natl Cancer Inst.*, 7:96:13:1040-1, 2004

--Ghadirian P, Lubinski J, Lynch H, Neuhausen SL, Weber B, Isaacs C, Baruch RG, Randall S, Ainsworth P, Freidman E, Horsman D, Tonin P, **Foulkes WD**, Tung N, Sun P, Narod SA. Smoking and the risk of breast cancer among carriers of BRCA mutations. *Int J Cancer*,

110:413-6, 2004

--Jernstrom H, Lubinski J, Lynch HT, Ghadirian P, Neuhausen S, Isaacs C, Weber BL, Horsman D, Rosen B, **Foulkes WD**, Friedman E, Gershoni-Baruch R, Ainsworth P, Daly M, Garber J, Olsson H, Sun P, Narod SA. Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. *J Natl Cancer Inst.* 21:96:14:1094-8, 2004

--Kotar K, Brunet JS, Moller P, Hugel L, Warner E, McLaughlin J, Wong N, Narod SA, **Foulkes WD**. Ratio of female to male offspring of women tested for BRCA1 and BRCA2 mutations. *J Med Genet.*, 41:e103, 2004

--Metcalf K, Lynch HT, Ghadirian P, Tung N, Olivotto I, Warner E, Olopade OI, Eisen A, Weber B, McLennan J, Sun P, **Foulkes WD**, Narod SA. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. *J Clin Oncol.* 22:2328-35, 2004

--Narod SA, **Foulkes WD**. BRCA1 and BRCA2: 1994 and beyond. *Nat Rev Cancer*, 4:665-76, 2004

--Oros KK, Ghadirian P, Greenwood CM, Perret C, Shen Z, Paredes Y, Arcand SL, Mes-Masson AM, Narod SA, **Foulkes WD**, Provencher D, Tonin PN. Significant proportion of breast and/or ovarian cancer families of French Canadian descent harbor 1 of 5 BRCA1 and BRCA2 mutations. *Int J Cancer*, 112:411, 2004

--Robson ME, Chappuis PO, Satagopan J, Wong N, Boyd J, Goffin JR, Hudis C, Roberge D, Norton L, Begin LR, Offit K, **Foulkes WD**. A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. *Breast Cancer Res.*, 6:R8-R17, 2004

--Thiffault I, **Foulkes WD**, Marcus VA, Farber D, Kasprzak L, MacNamara E, Wong N, Hutter P, Radice P, Bertario L, Chong G. Putative common origin of two MLH1 mutations in Italian-Quebec hereditary non-polyposis colorectal cancer families. *Clin Genet.* 662:137-43, 2004

--Thiffault I, Schwartz CE, Der Kaloustian V, **Foulkes WD**. Mutation analysis of the tumor suppressor PTEN and the glypican 3 (GPC3) gene in patients diagnosed with Proteus syndrome. *Am J Med Genet.* 130A(2):123, 2004

Friedman, Gad

--Fallone CA., Barkun AN, Mayrand S, Wakil G., **Friedman, G.**, Szilagi A, Wheeler C., Ross D. There is no difference in the disease severity of gastro-esophageal reflux disease between patients infected and not infected with *Helicobacter pylori*. *Clinical Trial. Journal article. Randomized Controlled Trial. Alimentary Pharmacology & Therapeutics.* 20:761-8, 2004

Frisch, Gershon

--Nikolas, T., **Frisch, GD**, Optowsky, A.R., Arons, R., Radhakrishnan, J. Awareness of kidney disease in the US population: Findings from the National Health and Nutrition Examination

Survey (NHANES) 1999-2000, 44:185-197, 2004

Galipeau, Jacques

--Annabi, B., Naud, E., Lee, Y.T., Eliopoulos, N., **Galipeau, J.** Vascular Progenitors derived from Murine Bone Marrow Stromal Cells are Regulated by Fibroblast Growth Factor and are Avidly Recruited by Vascularizing Tumors. *Journal of Cellular Biochemistry* 91:1146–1158, 2004

--Eliopoulos, N., Lejeune, L., Martineau, D., **Galipeau, J.** Human-compatible collagen matrix for prolonged and reversible systemic delivery of erythropoietin in mice from gene-modified marrow stromal cells. *Molecular Therapy* 10:741-748, 2004

--Samani A.A., Chevet, E., Fallavollita, L., **Galipeau, J.**, Brodt, P. Loss of Tumorigenicity and Metastatic Potential in Carcinoma Cells Expressing the Extracellular Domain of the Type 1 Insulin-Like Growth Factor Receptor. *Cancer Research* 64, 3380-3385, 2004

--Stagg, J., Wu, J.H., Bouganim, D., **Galipeau, J.** GM-CSF and IL-2 Fusion cDNA for Cancer Gene Immunotherapy. *Cancer Research* 64(24): 8795-9, 2004.

--Stagg, J., Lejeune, L., Paquin, A., **Galipeau, J.** Marrow stromal cells for interleukin-2 delivery in cancer immunotherapy. *Human Gene Therapy* 15:597–608, 2004

Germinario, Ralph

--Colby-Germinario SP, Chalifour LE, Antonecchia A and **Germinario RJ.** Antiretroviral protease inhibitors prevent 16 muscle cell fusion by reducing calpain activity. *AIDS Res Hum Retroviruses* 20: 1057-1062, 2004

--Stojanova A, Caro C, Jarjour RJ, Oster SK, Penn LZ and **Germinario RJ.** Repression of the human immunodeficiency virus type-1 long terminal repeat by the c-Myc oncoprotein. *J Cell Biochem* 92: 400-413, 2004

Greenaway, Christina

Greenaway C. Guinea Worm Disease (Dracunculiasis). *Can Med Assoc J.* 170(4):495-500, 2004

Hilzenrat, Nir

--Hanuka N, Sikuler E, Tovbin D, Neville L, Nussbaum O, Mostoslavsky M, Orgel M, Yaari A, Manor S, Dagan S, **Hilzenrat N**, Shemer-Avni Y. Hepatitis C virus infection in dialysis and chronic liver patients: Viraemia dependent anti-E2-antibody response. *J Med Virol.* 73:529-535, 2004

Hoffer, L. John

--**Hoffer, L.J.**, Elian, K.M.. Parenteral vitamin B12 therapy of hyperhomocysteinemia in end-stage renal disease. *Clinical and Investigative Medicine*. 27:10-13, 2004

--**Hoffer, L.J.** Homocysteine transsulfuration and remethylation. *Metabolism* 53:1480-3, 2004

Honos, George

--Hemmelgam BR, Zamke KB, Campbell NRC, Feldman RD, McKay DW, McAllister FA, Khan N, Schiffrin EL, Myers MG, Bolli P, **Honos G**, Lebel M, Levine M, Padwal R, for the Canadian Hypertension Education Program, Evidence based Recommendations Task Force. The 2004 Canadian Hypertension Education Program recommendations for the management of hypertension: Part I - Blood pressure measurement, diagnosis, and assessment of risk. *Can J Cardiol.*, 20:31-40, 2004

--Khan NA, McAlister FA, Campbell NRC, Feldman RD, Rabkin S, Mahon J, Lewanczuk R, Zamke KB, Hemmelgarm B, Level M, Levine M, Herbert C, for the Canadian Hypertension Education Program. The 2004 Canadian Recommendations for the Management of Hypertension: Part II - Therapy. *Can J Cardiol.* 20:41-54, 2004

--Cannon CP, Braunwald E, McCabe CH et al. Comparison of intensive and moderate lipid lowering with statins after acute coronary syndromes.(PROVE IT). *N Engl J Med.*, 350:1495-1504, 2004

--Jamieson WRE et al. Canadian Cardiovascular Consensus 2004: Surgical Management of Valvular Heart Disease. *Can J Cardiol.*, 20 Suppl E: 1E-120E, 2004

Kahn, Susan

--**Kahn, S.R.**, M'lan, C.E., Lamping, D.L., Kurz, X., Bérard, A., Abenhaim, L. for the VEINES Study Group. The influence of venous thromboembolism on quality of life and severity of chronic venous disease. *J Thromb Haemost.*, 2:2146-2151, 2004

--**Kahn, S.R.** Recurrent venous thromboembolism in men and women (letter). *N Engl J Med*, 351(19):2015-2018, 2004

--Kovacs, M.J., Kearon, C., Rodger, M., Anderson, D.R., Turpie, A.G.G., Bates, S.M., Desjardins, L., Douketis, J., **Kahn, S.R.**, Solymoss, S., Wells, P.S. Single-arm study of bridging therapy with low-molecular-weight heparin for patients at risk of arterial embolism who require temporary interruption of warfarin. *Circulation*, 110:1658-1663, 2004

--Dranitsaris, G., **Kahn, S.R.**, Stumpo, C., Paton, T., Martineau, J., Smith, R., and Ginsberg, J. Pharmacoeconomic analysis of Fondaparinux versus Enoxaparin for the prevention of thromboembolic events in orthopedic surgery patients. *Am J Cardiovasc Drugs*, 4:325-333, 2004

--**Kahn, S.R.** Venous thrombosis in long-haul travelers (letter). *Arch Int Med*, 164:1699-1700, 2004

--**Kahn, S.R.** (commentator). Review: elastic compression stockings prevent post-thrombotic syndrome in patients with deep venous thrombosis. *Evid Based Med*, 9:109, 2004

--**Kahn, S.R.** Review: Elastic compression stockings prevent the postthrombotic syndrome in deep venous thrombosis. *ACP J Club*,141:10, 2004

--Sullivan, S.D., Davidson, B.L., **Kahn, S.R.**, Muntz, J.E., Oster, G., Raskob, G. A cost-effectiveness analysis of fondaparinux sodium compared with enoxaparin sodium as prophylaxis against venous thromboembolism: use in patients undergoing major orthopaedic surgery. *Pharmacoeconomics*, 22:605-20, 2004

--Kearon, C., Ginsberg, J.S., Anderson, D.R., Kovacs, M., Wells, P., Julian, J., MacKinno, B., Demers, C., Douketis, J., Turpie, A.G.G., van Nguyen, P., Green, D., Kassis, J., **Kahn, S.R.**, Solymoss, S., Desjardins, L., Geerts, W., Johnston, M., Weitz, J., Hirsh, J., Gent, M. A comparison of 1 month with 3 months of anticoagulation for a first episode of venous thromboembolism provoked by a transient risk factor. *J Thromb Haemost*, 2:743-749, 2004

--**Kahn, S.R.**, M'lan, C.E., Lamping, D.L., Kurz, X., Bérard, A., Abenhaim, L. for the VEINES Study Group. Relationship between clinical classification of chronic venous disease and patient-reported quality of life: Results from an international cohort study. *J Vasc Surg*, 39:823-8, 2004.

--*Haber, M., *Golan, E., *Azoulay, L., Shrier, I., **Kahn, S.R.** Reliability of a device measuring triceps surae muscle fatigability. *Br J Sports Medicine* 38:163-7, 2004

--**Kahn, S.R.**, Ginsberg, JS. Relationship between deep venous thrombosis and the postthrombotic syndrome. *Arch Intern Med*, 164:17-26, 2004

Khanna, Manish

--Fundyler O, Khanna M, Smoller BR. Metalloproteinase-2 expression correlates with aggressiveness of cutaneous squamous cell carcinomas. *Mod Pathol*. 17(5):496-502, 2004

Karaplis, Andrew C.

--Bai X, Miao D, Li J, Goltzman D and **Karaplis AC**. Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal p12. phosphate wasting disorders. *Endocrinology* 145: 5269-5279, 2004

--Shin HI, Divieti P, Sims NA, Kobayashi T, Miao D, **Karaplis AC**, Baron R, Bringhurst R and Kronenberg HM. Gp130-mediated signaling is necessary for normal osteoblastic function in vivo and in vitro. *Endocrinology* 145:1376-1385, 2004

--Soroceanu MA, Miao D, Bai XY, Su H, Goltzman D and **Karaplis AC**. Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis. *J Endocrinol* 183:203-216, 2004

Langleben, David

--Barst RJ, **Langleben D**, Frost A, Horn EM, Oudiz R, Shapiro S, McLaughlin V, Hill N, Tapsos VF, Robbins IM, Zwicke D, Duncan B, Dixon RAF, Frumkin LR. Sitaxsentan therapy for pulmonary arterial hypertension. *Am J Respir Crit Care Med.*, 169:441 - 447, 2004

--Simonneau G, Galie N, Rubin LJ, **Langleben D**, Seeger W, Domenighetti G, Gibbs S, Lebrec D, Speich R, Beghetti M, Rich S, Fishman A. Clinical classification of pulmonary hypertension. *J Am Coll Cardiol.*, 43:5S-12S, 2004

--**Langleben D**, Hirsch AM, Shalit E, Lesenko L, Barst RJ. Sustained symptomatic, functional and hemodynamic benefit with the selective endothelin - A receptor antagonist, sitaxsentan, in patients with pulmonary arterial hypertension: a one year follow-up study. *Chest* 126:1377 - 1381, 2004

--**Langleben D**, Brock T, Dixon R, Barst R. STRIDE 1: Effects of the Selective ET_A Receptor Antagonist, Sitaxsentan Sodium, in a Patient Population with Pulmonary Arterial Hypertension that meets Traditional Inclusion Criteria of Previous Pulmonary Artery Hypertension Trials. *J Cardiovasc Pharmacol*, 44:S80-S84, 2004

Leblanc, Andrea

--Roucou X., Gains M., **LeBlanc A**. The Neuroprotective Functions of Prion Protein. *J. Neurosc. Res.* 75:153-161, 2004

--Tounekti O., Zhang Y., Goodyer C.G., **LeBlanc A**. Proteasomal degradation of caspase-6 in 17 β -estradiol-treated neurons. *J. Neurochem*, 89:561-8, 2004

--Guo H., Albrecht S., Bourdeau M., Petzke T., Bergeron C., **LeBlanc A**. Active Caspase-6 and Caspase-6 cleaved Tau in neuropil threads, senile plaque associated neurites and neurofibrillary tangles in Alzheimer's Disease. *Am. J. Pathol.* 2004, 165: 523-531 (Commentary by Cribbs et al., *Am. J. Pathol.*, 165:353-355, 2004

Lipman, Mark

--Morin, N., Metrakos, P., Berman, K., Shen, Y., **Lipman, M**. Quantification of donor microchimerism in sex-mismatched porcine allotransplantation by competitive PCR, *BioTechniques*, 37:74-81, 2004

MacNamara, Elizabeth

--Payne, R.J. Hier, M.P., Tamilia, M., Young, J., **MacNamara, E.**, Black, M.J. Same Day Discharge after Total Thyroidectomy: The value of 6-hour serum parathyroid hormone and calcium levels. *Head and Neck*, 27:1-7, 2005

--Payne, R.J. Hier, M.P., Tamilia, M., Young, J., **MacNamara, E.**, Black, M.J. Benefits from 1 and 6-hour Parathyroid Hormone and Calcium Levels after Thyroidectomy. *Otolaryngology-*

Head and Neck Surgery, 131:63, 2004

--Thiffault, I., Hamel, N., Pal, T., McVety, S., Marcus, V.A., Farber, D., Cowie, S., Deschênes, J., Graham, T., Odefrey, F., Goldgar, D., Narod, S., Watters, A.K. **MacNamara, E.**, Du Sart, D., Chong, G., Foulkes, W. Germ-line truncating mutations in both MSH2 and BRCA2 in a single kindred. *British Journal of Cancer*, 90:483-491, 2004

Miller, Mark

--MacArthur RD, **Miller M**, Albertson T, et al. Adequacy of early empiric antibiotic treatment and survival in severe sepsis : Experience from the MONARCS trial. *Clin Infect Diseases*, 38: 284-288, 2004

--Taylor G, Gravel D, Johnston L (Canadian Nosocomial Infection Surveillance Program and the Canadian Hospital Epidemiology Committee including **Miller M**). Incidence of bloodstream infection in multicentre inception cohorts of hemodialysis patients. *Amer J of Infec Control*, 32(3), 155-160, 2004

--Loo V, Libman M.D., **Miller MA**, Bourgault A-M, Frenette CH, Kelly M, Michaud S, Nguyen T, Poirier L, Vibien A, Horn R, Laflamme PJ, René P. Clostridium difficile : a formidable foe. *CMAJ*, 171 :47-8, 2004

--Munday CJ, Boyd DA, Brenwald N, **Miller M**, et al. Molecular and kinetic comparison of the novel extended-spectrum B-lactamases (ESBL) CTX-M-25 and CTX-M-26. *Antimicrobial Agents and Chemotherapy*, Dec 2004, 48(12), p4829-4834.

--Fassier F, Robert Y, Arruda H, Beliveau C, Blanchard PW, Boisjoli G, Garon A, Lamarche Y, **Miller MA**. Le médecin et les infections transmissibles par le sang [The physician and blood-borne diseases]. Position Paper of the College of Physicians of Quebec. April 2004 [ISBN 2-920548-14-X

--**Miller MA**, Robert Y. Gérer le risque lié au personnel soignant infecté - les hôpitaux d'enseignement de l'Université de McGill: des précurseurs. [Managing the risks of infected healthcare workers - the teaching hospitals of McGill University: the forerunners.] *Official Bulletin of the College of Physicians of Quebec* 2004;XVIV(3):11

--The working group of the Quebec Hospital Association (AHQ) and the Association of Microbiologists and Infectiologists of Quebec (AMMIQ) (including **Miller MA**). La réutilisation du matériel médical à usage unique (MMU) [The reuse of single-use medical devices (SUMeD's)], Mai 2004.

Miller, Wilson

--Davison K, Mann KK, Waxman S, **Miller WH Jr**. JNK activation is a mediator of arsenic trioxide-induced apoptosis in acute promyelocytic leukemia cells. *Blood* 103:3496-3502, 2004.

--Morelli C, Sisci D, Del Rincon S, Garofalo C, Tu X, **Miller WH Jr**, Vecchione A, Sauter ER, Surmacz E. Insulin receptor substrate 1 interacts with estrogen receptor α and modulates its

transcriptional activity. *Oncogene*, 23: 7517-26, 2004.

--Witcher M, Shou HY, Guo Q, **Miller WH Jr**. The combination of retinoic acid and tumor necrosis factor overcomes the maturation block in a variety of retinoic acid resistant acute promyelocytic leukemia cells. *Blood*, 104: 3335-42, 2004

--Pettersson F, Couture MC, Hanna N, **Miller WH Jr**. Enhanced retinoid-induced apoptosis of MDA-231 breast cancer cells by PKC inhibitors involves activation of ERK. *Oncogene* 23: 7053-7066, 2004.

--Rousseau C, Nichol J, Pettersson F, Couture MC, **Miller WH Jr**. ER β sensitizes breast cancer cells to retinoic acid: Evidence of transcriptional cross-talk. *Mol Cancer Res* 2: 523-531, 2004.

--Côté S, McNamara S, Brambilla D, Bianchini A, Rizzo G, Grignani F, Nervi C, **Miller WH Jr**. The corepressor SMRT β promotes ligand-induced activation of mutated and wildtype retinoid receptors. *Blood*, 104: 4226-35, 2004.

--Del Rincon S, Guo Q, Morelli C, Shiu H, Surmacz E, **Miller WH Jr**. Retinoic acid mediates degradation of IRS-1 by the ubiquitin-proteasome pathway, via a PKC-dependant mechanism. *Oncogene* 23: 9269-79, 2004.

Monette, Joanne

--**Monette J.**, Monette M., Champoux N., Galbaud du Fort G., Wolfson C. Prévalence, efficacité et effets indésirables des neuroleptiques parmi les personnes âgées. *Revue de Gériatrie*, 29:2:131-6, 2004

Palayew, Mark

--**Palayew Mark**, Dajczman Esther, Klebansky William, Kupfer Pierre, Kreisman Harvey, Small David. Perception of discomfort by patients, physicians, and respiratory technicians during Flexible Bronchoscopy, *Journal of Bronchology*, 11:17-21, 2004

Rudski, Lawrence

--**Rudski LG**, Chow CM, Levine RA. Prosthetic Mitral Regurgitation Can be Mimicked by Color Flow Mapping: Avoiding Misdiagnosis. *J American Society of Echocardiography*, 17:829-33, 2004

--Levine RA, Messas E, Nathan NS, **Rudski LG**. New Understandings of Ischemic Mitral Egurgitation; The Marionette and its Masters. *European Journal of Echocardiography*, 5:313-17, 2004

--Beique F, Quang Hieu De Tran, Ma F., **Rudski L.**, Daves S., Angelini P. Anomolous right coronary artery originating from the left sinus of Valsalva. *Journal of Cardiothoracic and Vascular Anesthesia*, 18:788, 2004

Schipper, Hymen

--Borten O, Liberman A, Tuchweber B, Chevalier S, Ferland G, **Schipper HM**. Effects of dietary restriction and metal supplementation on the accumulation of iron-laden glial inclusions in the aging rat hippocampus. *Biogerontology*, 5:81-88, 2004

--**Schipper HM**. Glial heme oxygenase-1 in CNS injury and disease. In: Hertz L (ed.): Non-neuronal Cells of the Nervous System: Function and Dysfunction, *Adv Molec Cell Biol*, Elsevier, Amsterdam, 31:869-882, 2004

--**Schipper HM**. Heme oxygenase-1: Transducer of pathological brain iron sequestration under oxidative stress. In: LeVine S, Connor JR, Schipper HM (eds.). Redox-active Metals in Neurological Disorders. *Ann NY Acad Sci*, 1012: 84-93, 2004

--**Schipper HM**. Redox Neurology: Visions of an emerging subspecialty. In: LeVine S, Connor JR, Schipper HM (eds.). Redox-active Metals in Neurological Disorders. *Ann NY Acad Sci* 1012: 342-355, 2004.

--**Schipper HM**. Brain iron deposition and the free radical-mitochondrial theory of ageing. *Ageing Res Rev*, 3:265-301, 2004

--**Schipper HM**. Heme oxygenase expression in human central nervous system disorders. *Free Rad Biol Med*, 37:1995-2011, 2004

Silva, J. Enrique

--Alfadda A, DosSantos RA, Stepanyan Z, Marrif H and **Silva JE**. Mice with deletion of the mitochondrial glycerol-3-phosphate dehydrogenase gene exhibit a thrifty phenotype: effect of gender. *Am J Physiol Regul Integr Comp Physiol* 287:R147-R156, 2004

Small, David

--Rivera JA, Christopoulos S, **Small D** and Trifiro M. Hormonal manipulation of benign metastasizing leiomyomas: report of two cases and review of the literature. *J Clin Endocrinol Metab* 89: 3183-3188, 2004

Small, Peter

--Small, P. New Rhinitis Guidelines. *Allergy & Asthma*, p 4-7, 2004.

Szilagyi, Andrew

--**Szilagyi, A.**, Cohen, A., Vinokuroff, C., Darakhshan, A., Nathwani, U, Yesovitch, S. Deadaption and readaptation with lactulose: A case of occult colonic bacterial adaptation. *Can J Gastroenterol*, 18:677-680, 2004

--Karagozian, R, Turbide, C., **Szilagyi A**. Henoch-Schonlein Purpura Presenting with Ileal

Involvement in an Adult. Digestive Diseases and Sciences, 49:1722-1726, 2004

--**Szilagy A.** Redefining lactose as a conditional prebiotic. Can J Gastroenterol. 18,163-167, 2004

Tamilia, Michael

--Alfadda A and **Tamilia M.** Preeclampsia-like syndrome that is associated with severe hypothyroidism in a 20-week pregnant woman. Am J Obstet Gynecol 191: 1723-1724, 2004

Therrien, Judith

--Benzaquen BS, Webb GD, Colman JM, Williams WG, **Therrien J.** Arterial Switch Operation After Mustard Procedures in Adult Patients with Transposition of the Great Arteries: Is it Time to Revise our Strategy? Am Heart J., 147(3):E8, 2004

--Salehian O. Schwerzmann M, Merchant N, Webb GD, Siu SC, **Therrien J.** Assessment of systemic right ventricular function in patients with transposition of the great arteries using myocardial performance index: comparison with cardiac magnetic resonance imaging. Circulation, 110:3229-33, 2004

--Redington A, Smallhorn J, **Therrien J,** Webb GD. Chap. 44 Congenital Heart Disease, Braunwald, 7th Ed. 2004.

Wolkove, Norman

--Baltzan M, Kamel H, Rotaple M, **Wolkove N.** Pulmonary Rehabilitation Improves Function Capacity in Patients 80 Years or Older, Canadian Respiratory Journal, 11:407-413, 2004